Electra Therapeutics (NASDAQ:ETRA) Upgraded to “Strong-Buy” at Evercore

Posted by Geri Gentry on Oct 14th, 2026

Evercore upgraded shares of Electra Therapeutics (NASDAQ:ETRA – Free Report) to a strong-buy rating in a report released on Tuesday morning,Zacks reports.

A number of other research firms have also commented on ETRA. Jefferies Financial Group initiated coverage on Electra Therapeutics in a research report on Tuesday. They set a “buy” rating and a $32.00 price target on the stock. Wall Street Zen raised Electra Therapeutics to a “hold” rating in a research note on Saturday, September 26th. Cantor Fitzgerald initiated coverage on Electra Therapeutics in a report on Tuesday. They set an “overweight” rating on the stock. Finally, TD Cowen began coverage on Electra Therapeutics in a report on Tuesday. They set a “buy” rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Strong Buy” and an average price target of $34.00.

View Our Latest Research Report on Electra Therapeutics

Electra Therapeutics Price Performance

NASDAQ:ETRA opened at $8.61 on Tuesday. Electra Therapeutics has a 1 year low of $8.57 and a 1 year high of $15.50.

Insider Transactions at Electra Therapeutics

In related news, Director Carl L. Gordon purchased 1,333,333 shares of the firm’s stock in a transaction dated Monday, September 21st. The shares were acquired at an average cost of $15.00 per share, with a total value of $19,999,995.00. Following the completion of the purchase, the director directly owned 5,126,891 shares of the company’s stock, valued at $76,903,365. This trade represents a 35.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Orbimed Advisors Llc purchased 1,333,333 shares of the stock in a transaction that occurred on Monday, September 21st. The stock was bought at an average cost of $15.00 per share, with a total value of $19,999,995.00. Following the acquisition, the director owned 5,126,891 shares of the company’s stock, valued at $76,903,365. This represents a 35.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Electra Therapeutics Company Profile

(Get Free Report)

Electra Therapeutics, Inc is a clinical-stage biopharmaceutical company developing therapies for severe immune-mediated diseases. The company is focused on creating treatments designed to selectively remove disease-causing immune cells while preserving healthy immune cells.

Electra’s lead product candidate, ELA026, is an investigational antibody being developed for conditions involving harmful immune-cell activity. The company is evaluating the candidate in clinical studies for diseases including systemic sclerosis and immune thrombocytopenia.

Electra Therapeutics is headquartered in the United States and is focused primarily on advancing its pipeline through clinical development.